Skip to main content
Yan Zheng, MD, PhD
Yan Zheng, MD, PhD

Yan Zheng, MD, PhD

Assistant Member, St. Jude Faculty



PhD - Johns Hopkins University School of Medicine, Baltimore, MD
- Baylor University, Waco, TX
- Peking University Health Science Center, Beijing, China

Research Interests

  • RBC alloimmunization
  • Cancer immunotherapy

Selected Publications

Zheng Y, Tormey CA. The use of 4F-PCC to correct direct oral anticoagulant-induced coagulopathy: An observational analysis. Transfus Med. Apr 27, 2020. doi: 10.1111/tme.12683. [Epub ahead of print]

Zheng Y, Maitta RW. Alloimmunisation rates of sickle cell disease patients in the United States differ from those in other geographical regions. Transfus Med 26: 225-30, 2016.

Shameli A, Xiao W, Zheng Y, Shyu S, Sumodi J, Meyerson HJ, Harding CV, Maitta RW. A critical role for alpha-synuclein in development and function of T lymphocytes. Immunobiology 221:333-340, 2016.

Zheng Y, Hong H, Reeves HM, Maitta RW. Absolute immature platelet count helps differentiate thrombotic thrombocytopenic purpura from hypertension-induced thrombotic microangiopathy. Transfusion and Apheresis Science 51:54, 2014.

Zheng Y, George M, Chen F. Intravascular fasciitis involving the flank of a 21-year-old female: a case report and review of the literature. BMC Res Notes 7:118, 2014.

*Yasmin M, *Zheng Y, Cai D. Dysmegakaryocytopoiesis and maintaining platelet count in patients with plasma cell neoplasm. North American Journal of Medical Sciences 5:316, 2013. (* the two authors contributed equally)

Locke FL, Zha YY, Zheng Y, Driessens G, Gajewski TF. Conditional deletion of PTEN in peripheral T cells augments TCR-mediated activation but does not abrogate CD28 dependency or prevent anergy induction. J Immunol 191:1677, 2013.

Zheng Y, Zha Y, Spaapen RM, Mathew R, Barr K, Bendelac A, Gajewski TF. Egr2-dependent gene expression profiling and ChIP-Seq reveal novel biologic targets in T cell anergy. Mol Immunol 55:283, 2013.

Zheng Y, Zha Y, Driessens G, Locke F, Gajewski TF. Transcriptional regulator early growth response gene 2 (Egr2) is required for T cell anergy in vitro and in vivo. J Exp Med 209:2157, 2012.

Driessens G, Zheng Y, Locke F, Cannon JL, Gounari F, Gajewski TF. Beta-catenin inhibits T cell activation by selective interference with linker for activation of T cells-phospholipase C-gamma1 phosphorylation. J Immunol 186:784-790, 2010.

Driessens G, Zheng Y, Gajewski TF. Beta-catenin does not regulate memory T cell phenotype. Nat Med 16:513-514m 2010; author reply 514-515, 2010.

Zheng Y, Delgoffe GM, Meyer CF, Chan W, Powell JD. Anergic T cells are metabolically anergic. J Immunol 183:6095-6101, 2009.

Praveen K, Zheng Y, Rivas F, Gajewski TF. Protein kinase C theta focusing at the cSMAC is a consequence rather than cause of TCR signaling and is dependent on the MEK/ERK pathway. J Immunol 182:6022-6030, 2009.

Delgoffe GM, Kole TP, Zheng Y, Zarek PE, Matthews KL, Xiao B, Worley PF, Kozma SC, Powell JD. The mTOR kinase differentially regulates effector and regulatory T cell lineage commitment. Immunity 30:832-844, 2009.

Zheng Y, Zha Y, Gajewski TF. Molecular regulation of T-cell anergy. EMBO Reports 9:50-55, 2008.

Zheng Y, Collins SL, Lutz MA, Allen AN, Kole TP, Zarek PE, Powell JD. A role for mammalian target of rapamycin in regulating T cell activation versus anergy. J Immunol 178:2163-2170, 2007.

Powell JD, Zheng Y. Dissecting the mechanism of T-cell anergy with immunophilin ligands. Curr Opin Investig Drugs 7:1002-1007, 2006.

Allen A, Zheng Y, Gardner L, Safford M, Horton MR, Powell JD. The novel cyclophilin binding compound, sanglifehrin A, disassociates G1 cell cycle arrest from tolerance induction. J Immunol 172:4797-4803, 2004.

Last update: May 2020